• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·1066.HK
Share

Shandong Weigao Group Medical Polymer Company Limited Stocks

HK$ 3.26Last Updated 06.10.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

HK$ 1.82B

HK$ 3.26
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Shandong Weigao Group Medical Polymer Company Limited, founded in 2000 and situated in Weihai, People's Republic of China, specializes in the research, development, production, and distribution of disposable medical devices across mainland China. The company structures its extensive operations into several core divisions, including Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and other specialized segments. Its comprehensive product range covers a vast array of essential healthcare items. This includes devices for both vascular and non-vascular access, such as infusion sets, syringes, and specialized puncture needles, alongside various clinical collection kits. Shandong Weigao also provides solutions for wound care, offering sutures, healing dressings, cleaning products, and support devices for non-vascular catheters. In the realm of blood management, it supplies equipment for collection, storage, separation, and sterilization. The company is also a manufacturer of prefilled and pre-flush syringes, as well as instruments for blood collection and glucose monitoring. Its portfolio further extends to anesthesia consumables (general, local, and auxiliary), intensive care unit (ICU) equipment, and tools for both open and minimally invasive surgical procedures. Beyond disposables, the firm is a key producer of orthopedic devices, instruments for tumor and blood vessel interventions, and advanced medical components such as implantation materials and artificial organs. It also ventures into industrial manufacturing, producing medical-grade PVC granules, various plastic packaging materials, carton boxes, automated industrial equipment and parts, molds, and hemodialysis machines, encompassing Type I, Type II, and Type III medical devices. In addition to its manufacturing activities, Shandong Weigao offers a range of supporting services. These include finance leasing and factoring, wholesale distribution of Type I, surgical, and other disposable medical products. The company also provides asset management, enterprise consulting, management advisory, and comprehensive logistics and storage solutions, while actively exporting its products to international markets. Operating under recognized brands like Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing, the company serves a diverse clientele that includes hospitals, blood banks, various other medical facilities, and a broad network of distributors.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 1066.HK is 4.74 and suggests 47.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 00:49

Trump announced an "energy truce" between Ukraine and Russia. What do analysts think?

11.10.2026 21:01

A Warning Sign for the AI Market: DeepSeek Seeks $12 Billion—Key Details on the IPO as of October 11

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026